Amivantamab plus lazertinib vs osimertinib in first-line egfr-mutant advanced non-small cell lung cancer.

Nazmul Hasan, Misako Nagasaka
{"title":"Amivantamab plus lazertinib vs osimertinib in first-line egfr-mutant advanced non-small cell lung cancer.","authors":"Nazmul Hasan, Misako Nagasaka","doi":"10.1080/17476348.2025.2467338","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Thefirst line treatment landscape for patients with NSCLC harboring sensitizing <i>EGFR</i>mutations is rapidly evolving. Initially, osimertinib was the one and onlyoption over earlier generation EGFR inhibitors based on the positive PFS and OSresults from the FLAURA study.</p><p><strong>Areascovered: </strong>Thispaper reviews and compares the pivotal studies that led to the approval ofcombination treatment with a focus on the efficacy and safety of amivantamabplus lazertinib in the front-line setting. The literature reviewed in thispaper primarily includes key studies published in well-established journals andoncological conferences, such as ASCO, ESMO, and NEJM, between 2018 and 2024.</p><p><strong>Expertopinion: </strong>Recent advancements,including the results of FLAURA-2 and MARIPOSA, have introduced combinationtherapies that demonstrate enhanced efficacy.</p>","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of respiratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17476348.2025.2467338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Thefirst line treatment landscape for patients with NSCLC harboring sensitizing EGFRmutations is rapidly evolving. Initially, osimertinib was the one and onlyoption over earlier generation EGFR inhibitors based on the positive PFS and OSresults from the FLAURA study.

Areascovered: Thispaper reviews and compares the pivotal studies that led to the approval ofcombination treatment with a focus on the efficacy and safety of amivantamabplus lazertinib in the front-line setting. The literature reviewed in thispaper primarily includes key studies published in well-established journals andoncological conferences, such as ASCO, ESMO, and NEJM, between 2018 and 2024.

Expertopinion: Recent advancements,including the results of FLAURA-2 and MARIPOSA, have introduced combinationtherapies that demonstrate enhanced efficacy.

简介针对携带致敏表皮生长因子受体突变的 NSCLC 患者的一线治疗方案正在迅速发展。最初,基于FLAURA研究中积极的PFS和OS结果,osimertinib是替代早期EGFR抑制剂的唯一选择:本文回顾并比较了导致联合治疗获批的关键性研究,重点关注阿米万他单抗加拉唑替尼在一线治疗中的疗效和安全性。本文回顾的文献主要包括 2018 年至 2024 年间发表在 ASCO、ESMO 和 NEJM 等知名期刊和肿瘤学会议上的关键研究:最近的进展,包括 FLAURA-2 和 MARIPOSA 的研究结果,已经引入了显示出更强疗效的联合疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信